An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
News outlets are reporting that prescriptions for two popular weight-loss drugs — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) — are rising and expected to keep growing into 2025. In plain terms: more doctors are prescribing these medicines and more people are using them to lose weight or manage related health problems. The story is about a market and medical trend, not a single clinical discovery. Semaglutide and tirzepatide are man-made versions of hormones your body already uses to control hunger and blood sugar. Semaglutide acts like a gut hormone that tells your brain you’re full and slows how fast your stomach empties. Tirzepatide does something similar but mimics two different gut hormones at once, so it can reduce appetite and affect how the body handles sugar. Both are injected and were developed partly for diabetes treatment; their weight-loss effects were found in trials and then used more broadly. When journalists talk about a “growth trend” they’re summarizing prescription data and market forecasts — for example, how many prescriptions pharmacies fill or how manufacturers expect sales to rise. That kind of research looks at big-picture numbers: prescriptions, sales, and sometimes insurance coverage trends. It doesn’t prove new medical effects; it shows more people are being prescribed the drugs. The effect being reported is about uptake and demand, not a clinical trial showing improved outcomes. The size of the growth can be large in percentage terms because these drugs are new and in demand, but headlines don’t tell you about individual results or long-term success rates. Why this matters is straightforward. If more people use these drugs, there could be real benefits at a population level — fewer obesity-related illnesses like type 2 diabetes, high blood pressure, and heart disease — provided the drugs work for those people and are used safely. It also affects access and cost. Greater demand can strain supply, lead to shortages, and push prices up. Insurers and governments may change coverage rules, which affects who can realistically get these drugs. People considering these treatments should know the landscape is changing quickly. There are important caveats. These drugs have side effects — nausea, diarrhea, and sometimes more serious issues; long-term effects are still being studied. They require prescriptions and medical supervision. Not everyone responds the same way, and stopping the drugs often leads to some weight regain. There are also equity and ethical questions: with growing demand, some people who need injectable diabetes treatment might face shortages. Regulatory status varies by country and by specific use (diabetes versus weight loss), so availability and insurance coverage differ. The articles about “growth” describe trends, not new proof of safety or better health outcomes for everyone. Bottom line: prescriptions of semaglutide and tirzepatide are climbing into 2025, signaling big public interest and market change — but growing use brings both potential benefits and real questions about safety, access, and long-term effectiveness.
Source: BusinessWorld Online